Lee Heung-Man, Lim Hyun-Woo, Kang Hee Joon, Chae Sung-Won, Hwang Soon-Jae, Jung Kwang-Yoon, Woo Jeong-Soo
Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Korea.
Laryngoscope. 2006 Jun;116(6):966-9. doi: 10.1097/01.Mlg.0000216809.90196.83.
To assess the efficacy of treatment of a ranula in children by intralesional injection of OK-432.
Retrospective analysis of 13 cases.
Review of medical records of pediatric patients with ranula treated by OK-432 sclerotherapy from 2002 through 2005.
Among 13 cases, 9 were completely regressed by injection therapy alone. Three cases were incompletely regressed. One case was cured by surgical excision. The follow-up duration was 6 to 46 (mean 24.3) months. Adverse effects of OK-432 injection were tolerable, and no complication was observed.
On the basis of our experience, sclerotherapy with OK-432 was a safe and effective primary treatment for a ranula in children. Further study will be needed to conclude its long-term effectiveness.
评估瘤内注射溶链菌制剂（OK-432）治疗儿童舌下囊肿的疗效。
对13例病例进行回顾性分析。
回顾2002年至2005年接受OK-432硬化治疗的小儿舌下囊肿患者的病历。
13例中，9例仅通过注射治疗完全消退。3例消退不完全。1例通过手术切除治愈。随访时间为6至46个月（平均24.3个月）。OK-432注射的不良反应可耐受，未观察到并发症。
根据我们的经验，OK-432硬化治疗是儿童舌下囊肿安全有效的主要治疗方法。需要进一步研究以确定其长期疗效。
